News｜J-Pharma Co., Ltd.

Top＞News Lists

News Lists

J Pharma Co., Ltd. and Uniphar Announce Advancement of Nanvuranlat into Phase 3 Clinical Development Following FDA Alignment and Initial Patient Enrollment　Strategic partnership enables direct progression to Phase 3, bypassing additional Phase 2 study, as first patients are randomized in global trial

J-Pharma Announces jRCT Registration of an Investigator-Initiated Trial of Nanvuranlat in Combination with Immune Checkpoint Inhibitors for Biliary Tract Cancer — Toward Combination Therapy with Immune Checkpoint Inhibitors in First-Line Treatment for Biliary Tract Cancer —

JPH034 Phase I Clinical Trial Registered on ClinicalTrials.gov

Notice of Availability of Webinar Recording Hosted by the Cholangiocarcinoma Foundation – Advancing Understanding of the Global Phase 3 Clinical Trial of Nanvuranlat –

Notice of Webinar Hosted by the Cholangiocarcinoma Foundation – Advancing Understanding of the Global Phase 3 Clinical Trial of Nanvuranlat –

Notice of Listing on the Tokyo Stock Exchange Growth Market

J-Pharma Initiates Phase I Clinical Trial of JPH034 – First Subject Dosed

Notice of Approval for Listing on the Tokyo Stock Exchange Growth Market

The IND Safety Review for JPH034 Has Been Completed, Advancing Toward Initiation of a Phase 1 Clinical Trial in the United States

Nanvuranlat Beacon-BTC Global Phase III Clinical Trial Commences with First Site Activation

1 2 3 4 5 6 7 8